Endometrial Cancer Panel - Advanced

The Endometrial Cancer Panel – Advanced is a comprehensive molecular and immunohistochemistry (IHC) panel designed for the detailed evaluation of endometrial cancer. It assesses key biomarkers, including p53, mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2), POLE gene mutations, and next-generation sequencing (NGS) for DNA mutations and RNA fusions. Together, these tests help classify the tumour at a molecular level, provide prognostic information, identify hereditary cancer syndromes such as Lynch syndrome, and support personalised treatment planning.

Who Should Get This Test Done?

   This test may be recommended for:

●     Individuals diagnosed with endometrial (uterine) cancer requiring detailed tumour profiling.

●     Individuals whose healthcare provider recommends molecular classification to guide treatment decisions.

●     Individuals with suspected mismatch repair deficiency or possible Lynch syndrome.

●     Individuals with high-grade or recurrent endometrial cancer requiring additional genetic evaluation.

●     Individuals being considered for targeted therapies or immunotherapy based on tumour biomarkers.

Why Consider This Test?

   This test:

●     Provides a comprehensive molecular profile of endometrial cancer in a single panel.

●     Identifies MMR deficiency and helps screen for Lynch syndrome.

●     Detects POLE mutations and p53 abnormalities that aid in tumour classification and prognosis.

●     Uses next-generation sequencing to identify clinically relevant DNA mutations and RNA fusions.

●     Supports personalised treatment decisions, including the selection of targeted therapies and immunotherapy where appropriate.

More Information

The Endometrial Cancer Panel – Advanced combines immunohistochemistry (IHC) with next-generation sequencing (NGS) to evaluate important biomarkers involved in endometrial cancer. The panel includes p53 IHC, MLH1, MSH2, MSH6, PMS2, POLE gene mutation analysis, and comprehensive DNA and RNA analysis through OncoFocus-NEXT. These biomarkers help classify tumours according to current molecular classification systems and provide valuable information for diagnosis, prognosis, hereditary cancer assessment, and treatment planning. The results are interpreted along with histopathological findings and the patient’s clinical history.

Other Names

●     Advanced Endometrial Cancer Molecular Panel

●     Endometrial Carcinoma Comprehensive Genomic Panel

●     Endometrial Cancer Biomarker Panel

●     Endometrial Cancer NGS and IHC Panel

●     Comprehensive Endometrial Cancer Profiling Panel